Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
The purpose of the study was to identify subgroups of advanced cancer patients who experienced grade 3-4 toxicities as reported by their oncologists as well as identify the demographic, clinical, and treatment symptom characteristics as well as QoL outcomes associated with distinct profiles of each patient. A prospective, multicenter, observational study was conducted with advanced cancer patients of 15 different hospitals across Spain. After three months of systemic cancer treatment, participants completed questionnaires that evaluated psychological distress (BSI-18), quality of life (EORTC QLQ-C30) and fatigue (FAS). The most common tumor sites for the 557 cancer patients with a mean age of 65 years were bronchopulmonary, digestive, and pancreas. Overall, 19% of patients experienced high-grade toxicities (grade 3-4) during treatment. Patients with recurrent advanced cancer, with non-adenocarcinoma cancer, undergoing chemotherapy, and a showing deteriorated baseline status (ECOG > 1) were more likely to experience higher toxicity. Patients who experienced grade 3-4 toxicities during cancer treatment had their treatment suspended in 59% of the cases. Additionally, 87% of the patients had a dose adjustment or a cycle delayed in their treatment due to a high risk of dying during treatment. Future research should focus on identifying interventions to reduce high-grade toxicities and improve quality of life in cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Current oncology (Toronto, Ont.) - 30(2023), 10 vom: 19. Okt., Seite 9205-9216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Eun Mi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced cancer |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 01.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/curroncol30100665 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363796347 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363796347 | ||
| 003 | DE-627 | ||
| 005 | 20231226094114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/curroncol30100665 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363796347 | ||
| 035 | |a (NLM)37887565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Eun Mi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The purpose of the study was to identify subgroups of advanced cancer patients who experienced grade 3-4 toxicities as reported by their oncologists as well as identify the demographic, clinical, and treatment symptom characteristics as well as QoL outcomes associated with distinct profiles of each patient. A prospective, multicenter, observational study was conducted with advanced cancer patients of 15 different hospitals across Spain. After three months of systemic cancer treatment, participants completed questionnaires that evaluated psychological distress (BSI-18), quality of life (EORTC QLQ-C30) and fatigue (FAS). The most common tumor sites for the 557 cancer patients with a mean age of 65 years were bronchopulmonary, digestive, and pancreas. Overall, 19% of patients experienced high-grade toxicities (grade 3-4) during treatment. Patients with recurrent advanced cancer, with non-adenocarcinoma cancer, undergoing chemotherapy, and a showing deteriorated baseline status (ECOG > 1) were more likely to experience higher toxicity. Patients who experienced grade 3-4 toxicities during cancer treatment had their treatment suspended in 59% of the cases. Additionally, 87% of the patients had a dose adjustment or a cycle delayed in their treatment due to a high risk of dying during treatment. Future research should focus on identifying interventions to reduce high-grade toxicities and improve quality of life in cancer patients | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a advanced cancer | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a toxicities | |
| 700 | 1 | |a Jiménez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Galán-Moral, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Coca-Membribes, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Montes, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Sorribes, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a García-Torralba, Esmeralda |e verfasserin |4 aut | |
| 700 | 1 | |a Puntí-Brun, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gil-Raga, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Cano-Cano, Juana |e verfasserin |4 aut | |
| 700 | 1 | |a Calderon, Caterina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology (Toronto, Ont.) |d 1998 |g 30(2023), 10 vom: 19. Okt., Seite 9205-9216 |w (DE-627)NLM09444482X |x 1718-7729 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:10 |g day:19 |g month:10 |g pages:9205-9216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/curroncol30100665 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 10 |b 19 |c 10 |h 9205-9216 | ||